ANXA9 and colorectal carcinoma: These findings establish ANXA9 not only as a marker of a poor prognosis but also as a functionally relevant driver of chemoresistance, suggesting that targeting ANXA9 may provide a novel therapeutic avenue for managing drug-resistant CRC.